Posted by Michael Wonder on 07 Jun 2023
UCB receives new European Commission approvals for Bimzelx (bimekizumab) for the treatment of psoriatic arthritis and axial spondyloarthritis
7 June 2023 - Bimekizumab is the first and only IL-17A and IL-17F inhibitor approved in the European Union for active psoriatic arthritis and active axial spondyloarthritis.
UCB today announced that the European Commission has granted marketing authorisation for Bimzelx (bimekizumab) for the treatment of adults with active psoriatic arthritis and adults with active axial spondyloarthritis including non-radiographic axSpA and ankylosing spondylitis.
